Charles O'Bryan-Tear

Charles O'Bryan-Tear

No más puestos en curso

Fortuna: 215 961 $ al 31/03/2024

69 años
Health Technology
Consumer Services
Commercial Services

Perfil

Charles Gillies O'Bryan-Tear worked as a Medical Director at Bristol-Myers Squibb Pharmaceuticals Ltd., Director at Affibody AB, Interim Medical Director at Genzyme Therapeutics Ltd., Vice President-Research & Development at GlaxoSmithKline Biologicals NV, Chief Medical Officer at Algeta ASA, and Chief Medical Officer at Scancell Holdings Plc.
He holds a doctorate from the University of Cambridge and an MBA from Cranfield University.

Participaciones conocidas en empresas públicas

EmpresaFechaNúmero de accionesValoraciónFecha de valoración
30/06/2023 120 373 ( 0.04% ) 215 961 $ 31/03/2024

Antiguos cargos conocidos de Charles O'Bryan-Tear.

EmpresasCargoFin
CLARITY PHARMACEUTICALS LTD Director/Board Member 15/05/2023
SCANCELL HOLDINGS PLC Chief Tech/Sci/R&D Officer -
Corporate Officer/Principal -
Corporate Officer/Principal -
ALGETA ASA Chief Tech/Sci/R&D Officer -
Ver el detalle de la experiencia de Charles O'Bryan-Tear.

Formación de Charles O'Bryan-Tear.

University of Cambridge Doctorate Degree
Cranfield University Masters Business Admin

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Charles O'Bryan-Tear.

Empresas relacionadas

Empresas cotizadas2
SCANCELL HOLDINGS PLC

Health Technology

CLARITY PHARMACEUTICALS LTD

Health Technology

Empresas privadas5

Health Technology

Commercial Services

Health Technology

Health Technology

Health Technology

  1. Bolsa de valores
  2. Insiders
  3. Charles O'Bryan-Tear